Methods and compositions for treatment of glaucoma and related conditions
US12161629B2 · kind B2 · utility
0Cited by
68References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2019 |
| Grant date | Dec 10, 2024 |
| Priority date | — |
| Expiry date | Sep 21, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P27/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods, compositions and kits comprising alpha-adrenergic antagonists, such as phentolamine, for the treatment of glaucoma, ocular hypertension, and/or other ocular disorders, such as non-arteritic anterior ischemic optic neuropathy or keratoconus, are provided. Said methods, compositions and kits may further comprise additional therapeutic agents, including prostaglandin analogues such as latanoprost, beta-adrenergic antagonists, alpha-adrenergic agonists, carbonic anhydrase inhibitors, cholinergic agonists, NMDA receptor antagonist, adenosine receptor antagonists, 5-HT2a receptor agonists, or Rho kinase inhibitors.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.